Pueraria mirifica is a Southeast Asian root plant used as an oral supplement or vaginal gel for menopausal symptoms, vaginal health, and bone maintenance. Its compounds strongly bind estrogen receptors, with medium evidence for vaginal restoration and reduced bone breakdown, and low, conflicted evidence for hot flashes, cholesterol, and wrinkles. Oral use carries inflammation, bleeding, liver, heart rhythm, and supplement-quality risks, giving vaginal gel a narrower risk profile. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Bone-Specific Alkaline Phosphatase (BAP) | No established target; reduction from individual baseline | Expected efficacy marker: oral dosing (20–50 mg/day) suppressed postmenopausal bone turnover over 24 weeks |
| LDL & HDL Cholesterol | No established target; LDL decrease and HDL increase from individual baseline | Expected efficacy marker: 100 mg/day oral dosing lowered LDL by 17% and raised HDL by 34% in 8 weeks, though 20–50 mg/day showed no change |
| Fasting Serum Triglycerides | <150 mg/dL (standard reference range) | Safety check: oral estrogenic stimulation can elevate hepatic triglyceride synthesis and cause progressive hypertriglyceridemia |
| High-Sensitivity C-Reactive Protein (hs-CRP) | No established target; stability relative to individual baseline | Safety check: clinical trial synthesis reported a doubling of serum C-reactive protein during oral use |
| ALT, AST & Complete Blood Count | ALT 7–56 U/L, AST 8–33 U/L, female hemoglobin 12.0–16.0 g/dL (standard reference range) | Safety check: screens for transient hepatic enzyme elevations, cholestasis, and transient anemia reported in Phase II trials |
| Endometrial Thickness & Vaginal Maturation Index (VMI) | No established target; endometrial thickness stability and VMI increase from individual baseline | Safety check and expected efficacy marker: confirms vaginal epithelial restoration while ruling out estrogen-induced endometrial proliferation or hyperplasia |
| Corrected QT Interval (QTc on 12-Lead Electrocardiogram) | No established target; stability from individual baseline | Safety check: detects estrogen-mediated potassium channel blockade and acquired long QT syndrome before torsades de pointes can occur |
Cadence: Baseline for all markers; resting 12-lead electrocardiogram at 2–4 weeks; fasting triglycerides, hs-CRP, ALT, AST, and complete blood count at 4 and 12–24 weeks; LDL and HDL cholesterol at 8 and 24 weeks; bone-specific alkaline phosphatase, vaginal cytology, and pelvic and breast ultrasound at 12–24 weeks (every 6 months).